Molecular neuroimaging of Parkinson's disease: association of motor and non-motor symptoms with synaptic density, dopaminergic and serotonergic systems

C-DASB binding in the insular cortex (p = 0.003), parietal lobe (p = 0.009), caudate (p < 0.001), and putamen (p = 0.002) were observed in PD compared to HC. Some baseline correlations emerged between imaging metrics and symptom scales in PD, though these were limited. Despite progression in motor impairment, autonomic dysfunction, and overall disability in PD, no significant longitudinal changes or group × time interactions were detected for molecular imaging measures. This study confirmed dopaminergic and serotonergic dysfunction in PD. Synaptic density did not differ between groups or change over time, suggesting synaptic loss may be minimal at mild-to-moderate disease stages. These findings highlight how different molecular imaging markers reflect distinct aspects and timescales of PD pathophysiology.

Authors

Institutions

Publication Details

Journal
Neuroimage Reports
Published
2026-03-31
DOI
https://doi.org/10.1016/j.ynirp.2026.100337
Primary Topic
Parkinson's Disease Mechanisms and Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Molecular neuroimaging of Parkinson's disease: association of motor and non-motor symptoms with synaptic density, dopaminergic and serotonergic systems

Silvia Rota, Mattia Veronese, Julia Schubert, Pavlos Zinzalias et al.
Neuroimage Reports
Parkinson's Disease Mechanisms and Treatments
article

Molecular neuroimaging of Parkinson's disease: association of motor and non-motor symptoms with synaptic density, dopaminergic and serotonergic systems

Silvia Rota, Mattia Veronese, Julia Schubert, Pavlos Zinzalias, Lucia Batzu, Alastair D. Reith, Christine A. Parker, Steve C.R. Williams, Nazneen Barwick, Sarah Lee
article en

Abstract

C-DASB binding in the insular cortex (p = 0.003), parietal lobe (p = 0.009), caudate (p < 0.001), and putamen (p = 0.002) were observed in PD compared to HC. Some baseline correlations emerged between imaging metrics and symptom scales in PD, though these were limited. Despite progression in motor impairment, autonomic dysfunction, and overall disability in PD, no significant longitudinal changes or group × time interactions were detected for molecular imaging measures. This study confirmed dopaminergic and serotonergic dysfunction in PD. Synaptic density did not differ between groups or change over time, suggesting synaptic loss may be minimal at mild-to-moderate disease stages. These findings highlight how different molecular imaging markers reflect distinct aspects and timescales of PD pathophysiology.

Neuroimage ReportsVol. 6(2)
University of Padua (IT), King's College London (GB), Age UK (GB), King's College Hospital (GB)
GlaxoSmithKline, National Institute for Health and Care Research, Department of Health and Social Care, NIHR Maudsley Biomedical Research Centre
Good health and well-being
Openalex Percentile: Top 25%
Parkinson's Disease Mechanisms and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.